2023
DOI: 10.1016/j.jaad.2023.04.069
|View full text |Cite
|
Sign up to set email alerts
|

OnabotulinumtoxinA improves oral aperture in patients with scleroderma: A small clinical trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2025
2025

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 22 publications
0
1
0
Order By: Relevance
“…Reports suggest that hyaluronidase contributes to the prevention and treatment of microstomia in systemic sclerosis or mixed connective tissue disease by hydrolyzing glucosaminidic and glycosidic bonds in hyaluronic acid and other connective tissue mucopolysaccharides [ 50 , 51 ]. Furthermore, improvements in microstomia have been observed in scleroderma patients treated with onabotulinumtoxin A, suggesting that multiple treatment approaches are available [ 52 ].…”
Section: Treatment Of Microstomiamentioning
confidence: 99%
“…Reports suggest that hyaluronidase contributes to the prevention and treatment of microstomia in systemic sclerosis or mixed connective tissue disease by hydrolyzing glucosaminidic and glycosidic bonds in hyaluronic acid and other connective tissue mucopolysaccharides [ 50 , 51 ]. Furthermore, improvements in microstomia have been observed in scleroderma patients treated with onabotulinumtoxin A, suggesting that multiple treatment approaches are available [ 52 ].…”
Section: Treatment Of Microstomiamentioning
confidence: 99%